Silence Therapeutics plc reported a significant decline in financial performance for the fiscal year ending December 31, 2025, with total revenue of $0.6 million, down from $43.3 million in 2024. This decrease was primarily attributed to the completion of obligations under the collaboration agreement with Hansoh, which had contributed $24.6 million in revenue in the previous year. Additionally, the company did not achieve any milestone payments from its collaboration with AstraZeneca in 2025, compared to $10 million in 2024. The total operating loss for the year was $91.1 million, an increase from a loss of $63.3 million in the prior year, driven by ongoing research and development expenses.
In terms of operational developments, Silence Therapeutics is advancing its product pipeline, particularly focusing on its lead candidate, divesiran (SLN124), which is in Phase 2 development for polycythemia vera (PV). The ongoing SANRECO trial is fully enrolled, with topline results expected in the third quarter of 2026. The U.S. Food and Drug Administration (FDA) has granted divesiran Fast Track and orphan drug designations, which may facilitate its development and potential market entry. The company is also preparing for Phase 3 readiness for zerlasiran (SLN360), aimed at treating cardiovascular disease associated with elevated lipoprotein(a) levels.
Strategically, Silence Therapeutics has undergone some organizational changes, including the appointment of Iain Ross as Interim Principal Executive Officer following the departure of the former CEO. The company is actively seeking a new CEO and has made additional board appointments to strengthen its leadership. The company’s workforce as of December 31, 2025, consisted of 88 full-time employees, a slight reduction from previous years, reflecting ongoing efforts to manage costs amid significant operating losses.
Looking ahead, Silence Therapeutics anticipates continued investment in its research and development activities, with a focus on advancing its siRNA product candidates. The company expects to incur significant expenses as it progresses through clinical trials and seeks regulatory approvals. As of the end of 2025, Silence Therapeutics reported cash and cash equivalents of $85.1 million, which it believes will be sufficient to fund operations into 2028. However, the company acknowledges the need for additional capital to support its ongoing development efforts and is exploring various financing options, including potential collaborations and equity financing.
In summary, Silence Therapeutics is navigating a challenging financial landscape while advancing its innovative siRNA therapeutic pipeline. The company is focused on achieving key clinical milestones and securing additional funding to support its long-term growth objectives.
About SILENCE THERAPEUTICS PLC
Silence Therapeutics plc is a biotechnology company specializing in RNA interference (RNAi) therapeutics, focusing on developing siRNA molecules to target diseases with significant unmet medical needs. Its key products include divesiran for polycythemia vera and zerlasiran for cardiovascular disease linked to elevated lipoprotein(a). With a robust pipeline and proprietary mRNAi GOLD platform, Silence aims to address critical health challenges while exploring partnerships for further development and commercialization.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.